{"id":36985,"date":"2017-03-01T00:04:09","date_gmt":"2017-03-01T04:04:09","guid":{"rendered":"http:\/\/blogs.sld.cu\/marionod\/?p=36985"},"modified":"2017-03-01T00:04:09","modified_gmt":"2017-03-01T04:04:09","slug":"new-horizons-in-the-management-of-ada-scid","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/marionod\/2017\/03\/01\/new-horizons-in-the-management-of-ada-scid\/","title":{"rendered":"New Horizons in the Management of ADA-SCID"},"content":{"rendered":"<p><a href=\"http:\/\/www.ada-scid.online\/%20\" target=\"_blank\">New Horizons in the Management of ADA-SCID <\/a><\/p>\n<p>Sitio de educaci\u00f3n para profesionales de la salud sobre la enfermedad rara Inmunodeficiencia Combinada Severa de la Adenosina Deaminasa(ADA-SCID),patrocinado por la editorial Springer<\/p>\n<p><span id=\"result_box\" class=\"\" lang=\"es\"><span title=\"is a rare, but dangerous disease whose patients have a malfunctioning immune system that leaves the body open to infection from bacteria and viruses.\">Inmunodeficiencia Combinada Severa de la Adenosina Deaminasa es una enfermedad rara, pero peligrosa cuyos pacientes tienen un sistema inmunol\u00f3gico que funciona mal que deja el cuerpo abierto a la infecci\u00f3n de bacterias y virus. <\/span><span title=\"It is vital that healthcare professionals (HCPs) who are presented with ADA-SCID patients understand the biology of the disease, know how to screen for it, and are aware of the current and emerging treatments.\n\n\">Es vital que los profesionales de la salud que se presentan con pacientes con ADA-SCID entiendan la biolog\u00eda de la enfermedad, sepan c\u00f3mo detectarla y sean conscientes de los tratamientos actuales y emergentes.<\/p>\n<p><\/span><span title=\"With New Horizons in the Management of ADA-SCID, it is our goal to facilitate this understanding by providing direct access to the latest research and commentary in the form of independent editorials, published articles, webinars and case studies.\n\n\">El sitio tiene el objetivo de facilitar este entendimiento proporcionando acceso directo a las \u00faltimas investigaciones y comentarios en forma de editoriales independientes, art\u00edculos publicados, webinars y estudios de caso.<\/p>\n<p><\/span><span title=\"Who is this website for?\n\">\u00bfPara qui\u00e9n es este sitio web?<br \/>\n<\/span><span title=\"All HCPs who are presented with ADA-SCID patients, particularly: Paediatric\/Adult Immunologists, Gene and Cell Therapy Clinicians, Transplant Specialists, Paediatricians and Haematologists\n\n\">Todos los HCP que se presentan con pacientes con ADA-SCID, en particular: Inmun\u00f3logos Pedi\u00e1tricos \/ Adultos, Especialistas en Trasplantes, Especialistas en Trasplantes, Pediatras y Hemat\u00f3logos<\/p>\n<p><\/span><span title=\"What does New Horizons in the Management of ADA-SCID offer?\n\n\">\u00bfQu\u00e9 ofrece este sitio?<\/p>\n<p><\/span><span title=\"\u2022Summaries of the latest research with access to the full text articles\n\">\u2022 Res\u00famenes de las \u00faltimas investigaciones con acceso a los art\u00edculos de texto completo<br \/>\n<\/span><span title=\"\u2022Interviews with the leading experts\n\">\u2022 Entrevistas con los principales expertos<br \/>\n<\/span><span title=\"\u2022Webinars\n\">\u2022 Webinars<br \/>\n<\/span><span title=\"\u2022Interactive patient-case studies\">\u2022 Estudios de casos interactivos de pacientes<\/span><\/span><\/p>\n<p>Idioma: ingl\u00e9s<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Horizons in the Management of ADA-SCID Sitio de educaci\u00f3n para profesionales de la salud sobre la enfermedad rara Inmunodeficiencia Combinada Severa de la Adenosina Deaminasa(ADA-SCID),patrocinado por la editorial Springer Inmunodeficiencia Combinada Severa de la Adenosina Deaminasa es una enfermedad rara, pero peligrosa cuyos pacientes tienen un sistema inmunol\u00f3gico que funciona mal que deja el [&hellip;]<\/p>\n","protected":false},"author":126,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[64,2118,283],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts\/36985"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/users\/126"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/comments?post=36985"}],"version-history":[{"count":1,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts\/36985\/revisions"}],"predecessor-version":[{"id":36986,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts\/36985\/revisions\/36986"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/media?parent=36985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/categories?post=36985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/tags?post=36985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}